Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells.
This study describes the effects of the glucolipid synthase inhibitor P4, (DL-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol ), on various functional and phenotypic parameters of 5T33 murine myeloma cells. Cell recovery was reduced by >85% following incubation of the cells for 3 days in the presence of 4 microM P4 (the IC50 concentration). Both cytostatic and cytotoxic inhibition was observed with tumour cell metabolic activity and clonogenic potential reduced to 42% and 14% of controls, respectively, and viability reduced to 52%. A dose-dependent increase in cells undergoing apoptosis (from 7% to 26%) was also found. P4 induced a decrease in the number of cells expressing H-2 Class I and CD44, and a large increase in cells expressing H-2 Class II and the IgG2b paraprotein. It did not affect surface expression of CD45 or CD54 (ICAM-1). Based on these alterations in tumour cell growth, adhesion molecule expression and potential immunogenicity, it is anticipated that P4 will provide a novel therapeutic approach for the treatment of multiple myeloma. In addition, given that essentially all tumours rely heavily on overexpressed or abnormal glucosphingolipids for growth, development and metastasis, glucolipid synthase inhibitors may prove to be universally effective anti-cancer agents.
Manning
L S
LS
Research Centre, Royal Perth Hospital, Western Australia, Australia.
Radin
N S
NS
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006017:Glycolipids / Q000378:metabolism*; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis* / Q000187:drug effects; D051379:Mice; D009025:Morpholines / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D009101:Multiple Myeloma / Q000235:genetics / Q000473:pathology*; D010641:Phenotype; D014407:Tumor Cells, Cultured / Q000502:physiology
D000970:Antineoplastic Agents; D006017:Glycolipids; D000949:Histocompatibility Antigens Class II; D009025:Morpholines; C033110:RV 538; D005964:Glucosyltransferases